Gene Expression Profile Associated With Neural Tube Defects Among Infants Attending Muhimbili National Hospital And Muhimbili Orthopaedic Institute In Tanzania

Mariam Sadallah

Muhimbili University of Health and Allied Sciences

Evelyne Neema Assenga (✉ eassenga@yahoo.com)

Muhimbili University of Health and Allied Sciences <https://orcid.org/0000-0002-2281-2822>

Charles Pallangyo

Muhimbili University of Health and Allied Sciences

Karim Manji

Muhimbili University of Health and Allied Sciences

Research article

Keywords: Neural tube defects, gene expression profile, Methylenetetrahydrofolate reductase [MTHFR] gene

Posted Date: August 6th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-18083/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Neural tube defects (NTDs) are severe congenital anomalies of the central nervous system. The specific cause is not known, though several factors including gene variants involving the folate metabolism have been implicated in the etiology. This study aimed at identifying the gene expression profile of selected genes known to be associated with NTDs among infants attending Muhimbili National Hospital (MNH) and Muhimbili Orthopaedic Institute (MOI).

Methods: We conducted a matched case control study involving infants who were attending MNH and MOI during 6 months of the study period. Each case was matched with two controls by gestational age, sex and birth weight. Whole blood samples were collected from all study participants for genetic analysis. Total RNA was isolated using Qiagen RNA blood mini kit, and reversed transcribed into complementary DNA (cDNA) using Super Script II Reverse Transcriptase cDNA Synthesis kit. Real-time polymerase chain reaction was performed on extracted cDNA by a Light Thermal Cycler 480 machine using specific primers for studied genes to determine their expression levels. Results were analysed by GraphPad Prism 5Software, using Student t-test, and Bonferroni post hoc statistical tests. A p value of < 0.05 was considered to be statistically significant.

Results: The study recruited 50 cases and 100 controls. Among eight studied genes, we found significantly low expression of Methylenetetrahydrofolate reductase [*MTHFR*] gene among cases than controls (p=0.006). Expression of others genes were having variations and expressed at very low levels in both cases and controls.

Conclusions: A low expression level of *MTHFR* gene was a significant risk factor for the occurrence of NTDs amongst infants attending MNH and MOI. We recommend gene expression analysis to be done on mothers of infants with NTDs to identify those at risk; and further mutational analysis to be done to enhance genetic counseling and therefore to prevent recurrence of NTDs.

Background

Neural tube defects (NTDs) are congenital malformations of the central nervous system including: the brain, spinal cord, and skull. These result from failure of the neural tube to close properly during fetal embryogenesis around the third and fourth week of conception(1). Globally, 300,000 babies are born with NTDs per year(2),with the prevalence ranging from 0.2 to 10 per 1000 live births in specific geographical locations(3). In Tanzania, in the study done by Kishimba *et al*/ in 2012, NTDs were reported to have the highest incidence of 9 per 10,000 live births among selected external structural defects.(4).

The majority of NTDs have unknown etiology, involving complex interactions of genetic, nutritional and environmental factors(5). Despite normal or high folate supplementation pre and post conception, NTDs are still known to occur. There is overwhelming evidence that folate deficiency changes epigenetics and coding of methionine during embryogenesis and is thus implicated in the occurrence of NTDs. Studies have shown that genetic mutations involving the folate metabolism and planar cell polarity (PCP)

signaling pathways may be associated with an increased risk of NTDs(6). Gene variants that reduce the 'efficiency' of folate one-carbon metabolism have also been shown to increase the risk of NTDs. The Methylenetetrahydrofolate reductase (MTHFR) polymorphism C677T (rs1801133) has also been found to be associated with a 1.8-fold increased risk of NTDs, although this predisposition was detectable only in non-Hispanic populations(7). Similarly, in a study done in the Irish population, Kirke *et al* also found that both the homozygous (TT) and heterozygous (CT) genotypes for *MTHFR* C677T are associated with an increased risk of NTDs (odds ratio of 1.52 and 2.56 respectively)(8). In contrast, Hayati *et al* found no association between *MTHFR* C677T gene and NTDs in the Malaysian population as the homozygous genotype was absent in both cases and control groups(9).

Another significant risk factor detected is the Methylenetetrahydrofolate dehydrogenase (MTHFD-1) R653Q variant (rs2236225), a trifunctional enzyme that catalyses the conversion of tetrahydrofolate to 5,10-methylenetetrahydrofolate(10). Polymorphism in the Methylenetetrahydrofolate dehydrogenase-1-like(MTHFD-1-L), the gene for mitochondrial 10-formyl-tetrahydrofolate synthetase is also associated with an increased risk of NTDs(11).

Other genes such as Aminomethyltransferase (*AMT*) and Glycine dehydrogenase (*GLDC*) that encode enzymes of the glycine cleavage system have also been found to harbour a number of missense mutations resulting into NTDs. In the study done by Narisawa *et al* in 2011, two *AMT* gene variants *c.589G>C(D197H)* and *c.850G>C(V284L)* were identified in anencephaly and spinal bifida patients respectively, but they were absent in controls(12).

Planar cell polarity (PCP) genes such as *VANGL 1&2, Dvl2&Dvl3* which are essential for proper gastrulation in the neural tube formation in humans, have also been implicated as predisposing factors of isolated non-syndromic NTDs. Lei *et al*, detected 3 missense mutations in *VANGL 2* (*S84F (737C→T)*, *R353C (1543C→T)* and *F437S (1796T→C)*) from studying 163 stillborn babies and miscarried Chinese fetuses with NTDs, and these mutations were found to be absent in the control group(13). Similarly, Kibar *et al* identified three Italian patients with sporadic and familial NTDs to have missense mutations in *VANGL 1*(*V239I*, *R274Q*, and *M328T*) and these mutations were not identified in controls(14). Correspondingly, in a genetic study of a cohort of 473 NTD patients, De Marco *et al* found 8 rare mutations (5 in *Dvl2* and 3 in *Dvl3*) in eight patients which were not present in the controls(15). Therefore, the evidence is highly suggestive of a genetic component as a contributory risk factor for NTDs.

There is limited data on genetic etiology of NTDs in sub Saharan Africa of which Tanzania is part and where the incidence of NTDs remains high. Based on the evidence, a genetic causation cannot be excluded, which prompted this study. Therefore, we conducted this study to determine gene expression profile for eight genes which have been implicated in NTDs causation from previous studies. The aim was to determine the genetic contribution to NTDs in our setting, which may serve as a basis for genetic counseling of couples, so as to reduce the incidence of NTDs.

Methods

A hospital-based matched case control study was conducted over a period of six months from November 2016 to April 2017 at the Muhimbili National Hospital and Muhimbili Orthopaedic Institute in, Dares Salaam Tanzania. All infants who were receiving neonatal, general paediatrics, and neurosurgical services, during the study period were eligible.

Sampling procedure and sample size: A minimum of 50 cases and 100 controls were enrolled. A case was defined as infant with any type of NTDs and controls were those without detectable birth defects who met matching criteria. Consecutive sampling was used to enroll the cases until the sample size was reached. Two controls who matched a case by gestational age, birth weight and sex and who met the inclusion criteria were also selected using consecutive sampling among infants attending MNH/ MOI who had no obvious birth defects. Infants who met inclusion criteria but were very sick or whose mother did not consent were excluded.

Outcome variable: In this study, the dependent variable was the presence of the NTDs among the infants whilst for the independent variables; we selected eight genes which have been implicated from previous studies in NTDs etiology as shown in the Table 1.

Table 1. Primer sequences used for RT PCR

Gene	Forward5'→3'	Reverse5'→3'
<i>AMT</i>	GTGTTGGATAATGCCCTGCT	ACCGAGATCTCCACACCATC
<i>DVL-2</i>	GCTTTTGCAGGTGAATGACA	GAGGAGGAACCTGGATAGGC
<i>DVL-3</i>	GCTAAATGGAAGTGCAGG	CCGCTTGTGTCTTCTCATCA
<i>GAPDH**</i>	GTCAGTGGTGGACCTGACCT	TGCTGTAGCCAAATTCGTTG
<i>MTFHD-1</i>	TTCATCCCATGCACACCCAA	ATGCATGGGTGCACCAACTA
<i>MTFHD-1L</i>	GGACCCACTTTTGGAGTGAA	ATGTCCCCAGTCAGGTGAAG
<i>MTFHR</i>	AACCTGCCACTCAGGTGTCTTG	TGACAGTTTGCTCCCCAGGCAC
<i>VANGL-1</i>	TTACCTCCGATCCTGTGGAG	AGGCCTTCATCCACATTCAG
<i>VANGL-2</i>	CCAAACAGTGGACATTGGTG	GACTGCAGCCTCATGACAAA

**** GAPDH [Glyceraldehyde-3-Phosphate Dehydrogenase] was used as an internal control to ensure similar amounts of cDNA in the PCR mix**

Blood collection and laboratory procedures: We collected whole blood samples from all infants in the study for genetic analysis at MUHAS Genetic Laboratory. Blood samples were taken under aseptic technique using a 2milliliter syringe and 1milliliter volume of blood was collected into an EDTA vacutainer tube. The vacutainer were clearly labeled with the study identification number, time and date when the sample was drawn and sent to the laboratory in a cooler box within 2 hours of drawing the blood. In the laboratory, the samples were stored at -80°C freezer to ensure preservation of genetic materials before analysis.

RNA extraction and RT-PCR analysis: Total RNA for all 150 infants were prepared from the blood samples using QIAamp RNA Blood Mini Kit (Qiagen) following the manufacturer's recommendations, 1µg of the total RNA was reverse transcribed into cDNA using Super Script II Reverse Transcriptase First-Strand cDNA Synthesis kit in accordance to the manufacturer's protocol (Invitrogen). A real-time polymerase chain reaction(RT-PCR) was performed on extracted cDNA by a Light Cycler 480 Real Time PCR system (Roche) according to the manufacturer's protocol using primers indicated in the Table 1, and 2x SYBR Green Master Mix (Roche). *GAPDH* was used as the house-keeping gene and the results were analyzed using the delta-delta Ct method ($2^{-\Delta\Delta Ct}$ method) and presented as relative gene expressions(16).The PCR reaction was performed using standard RT-PCR conditions: 50°C for 2minutes, 95°C for10minutes, followed by 40 cycles of 95°C for 30seconds and 60°C for 1minute.

Data analysis: Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA) using the standard two-tailed Student's t-test for two data sets and ANOVA followed by Bonferroni post hoc tests for multiple data sets. A p-value of < 0.05 was considered to be statistically significant.

Results

Socio- demographic characteristics of infants in the study population

A total of 50 cases and 100 controls participated in this study. Most of the infants were <1month old (74%) with almost equal male to female ratio (52% male versus 48% female). The mean age of the participants was 1.78 ± 3.2 months with an age range of 1 to 11 months. Majority of the infants (92%) were delivered at term, with 66% having normal birth weights as shown in Table 2.

Table 2: Socio – demographic characteristics of 150 infants attending MNH and MOI

Child characteristic	Case(N=50)	Control(N=100)	Total (N=150)
Gender			
Male	26(52.0%)	52(52.0%)	78
Female	24(48.0%)	48(48.0%)	72
Gestational age			
Preterm	4(8.0%)	8(8.0%)	12
Term	46(92.0%)	92(92.0%)	138
Birth weight(kgs)			
< 2.5	5(10.0%)	10(10.0%)	15
2.5-3.5	33(66.0%)	66(66.0%)	99
>3.5	12(24.0%)	24(24.0%)	36
Mean age(months)	1.78 ± 3.259	1.78 ± 3.243	

Gene expression profile for eight (8) genes analyzed in the study population

We included eight genes of folate and planar cell polarity pathways which were selected from previously published NTDs researches as shown in the Table 1. After gene expression analysis, we found that there

was a significantly low level of expression of the *MTHFR* gene amongst the NTDs cases than amongst the controls ($p=0.006$). On the other hand, there were a lot of variations in the expression levels of other genes and these were expressed at very low levels in both controls and cases as shown in Figure 1.

Discussion

This study was conducted to determine the gene expression profile associated with NTDs among infants attending MNH and MOI. Findings revealed a significant low expression of *MTHFR* gene among cases than controls.

NTDs result from failure of closure of the neural tube during fetal embryogenesis. Evidence from studies done in different population groups strongly suggest that *MTHFR* polymorphism (*MTHFR C677T*) is associated with an increased risk of NTDs(7,8). In this study, DNA sequencing was not done, which is required for detecting specific gene mutation. However, the significantly low expression of *MTHFR* gene in the cases group could suggest the possibility of having variants with low enzyme activity amongst the cases with NTDs. The *MTHFR* gene plays a key role in folate and methylation cycles which are required for essential processes including; DNA synthesis, DNA/protein methylation, cell division, and tissue growth; especially in the rapidly developing cells(5). Thus, a defective gene variant could result in an impaired DNA synthesis or DNA methylation involved in the neurulation process which is essential during neural tube closure.

Folate pathway genes (those involved the uptake, transport and folate metabolic enzymes) have been intensively studied as candidates for NTD causation, in view of the role of folate in primary prevention. The main outputs of folate one-carbon metabolism (FOCM) are the generation of purines and pyrimidines for DNA synthesis during cell replication and the donation of methyl groups for regulation of gene, protein, and lipid function. Hence, genetic variants that reduce the efficiency of FOCM might increase the risk of NTDs either by compromising cell proliferation or the regulation of gene expression, or both. Indeed, when cells are derived from NTD foetuses and maintained in culture for several passage generations, around 30% of cell lines exhibited apparent inborn errors of folate metabolism, as indicated by diminished thymidylate biosynthesis(17); suggesting that genetic factors play a role in significant numbers of NTDs.

Despite decades of investigation into the genetic basis of NTDs, our knowledge of the inherited causative factors that impart disease risk remains incomplete. This is despite a wealth of information on the genetic requirements for neural tube closure in mice and many insights into the molecular basis of neurulation in lower vertebrates. Genetic counseling for NTDs is still empirical, based on population recurrence risk values, and there are no genetic tests for prospective parents in routine clinical usage. Genotyping for the C677T polymorphism of *MTHFR* and a few other folate-related genetic variants is available, but it is unclear how to interpret a particular parental *MTHFR* genotype in terms of NTD risk in a future pregnancy. Hopefully, full genome-wide assessment of potential risk variants, including coding, regulatory, and epigenetic modifications, in individuals with NTDs and their parents, will shed more light

into this. However, the extent to which this information will “explain” the occurrence of sporadic NTDs or predict future risk of NTD in families, remains to be determined. A further vital step in this work will be to link nutritional status, in terms of folate, vitamin B12 and other factors, to the putative genetic risk factors. It seems likely that only once all such factors are taken into account, can a reliable battery of tests be expected to emerge that has NTD predictive value.

The study found no association of NTDs and the expression levels of other genes such as *VANGL 1*, *VANGL2*, *Dvl2* and *Dvl3*. This is contrary to the studies done in China and Italy, which found a significant association between the incidence of NTDs and other genes in addition to *MTHFR* gene(10–15). This could be partly explained by the fact that none of these studies were done in Africa and also the other studies included aborted fetuses. Therefore, there is the likelihood that, gene expressions can be influenced by genetic diversity among different population groups and specific fetal developmental stages.

Strengths and limitations

This was a preliminary study, a first of its kind in Tanzania, whose objective was to screen for differences in the expression of implicated genes for NTDs between cases and controls, which has shown a genetic basis for NTDs; though the data is limited in functionally defining the genotypes and phenotypes which should be further investigated.

In this study, due to limited funding, further elucidation through DNA sequencing which is required for identifying specific genetic mutation/polymorphism could not be performed. Therefore, we cannot link the gene expression profile with specific gene variant/mutation(s) which might be a risk factor among the NTDs cases at the time of embryogenesis.

Conclusions

In conclusion, our findings suggesting that a low expression level of *MTHFR* gene was a significant risk factor associated with NTDs amongst infants attending MNH and MOI. We recommend gene expression analysis to be done on mothers of infants with NTDs to identify those at risk; and further mutational analysis to be done to enhance genetic counseling and therefore to prevent recurrence of NTDs.

List Of Abbreviations

cDNA: Complimentary Deoxyribonucleic Acid | GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase | **FOCM: Folate One-Carbon Metabolism** | MTHFD: Methylenetetrahydrofolate dehydrogenase | MTHFD: Methylenetetrahydrofolate reductase | MNH: Muhimbili National Hospital | MOI: Muhimbili Orthopaedic Institute | MUHAS: Muhimbili University of Health and Allied Sciences | NTDs: Neural Tube Defects | PCP: Planar Cell Polarity | RNA: Ribonucleic Acid | RT-PCR: Real-time Polymerase Chain Reaction |

Declarations

Ethical approval and consent to participate

Ethical clearance was obtained from the Institutional Review Board of Muhimbili University of Health and Allied Sciences (Ref.No.MU/PGS/SAEC/Vol.XVII/ and permission was sort from the Muhimbili National Hospital (Ref.No.MU/PGS/SAEC/Vol.XVII/ and Muhimbili Orthopaedic Institute authorities. All mothers signed informed consent forms prior to recruitment and received counseling on prevention of the future NTDs. The results from the genetic analysis were given through mobile phones for those who could be accessed. However, the results have been stored in a password secured folder whereby mothers who may need their individual information in future can be informed.

Consent for publication

Not applicable

Availability of data and materials

The database supporting the conclusion of this article is available with the author within reasonable request

Competing interests

The authors declare that they have no competing interests.

Funding

The study was conducted as part fulfillment of a master of medicine degree by dissertation which was funded by the Ministry of Health and Social Welfare in Tanzania, an estimated USD 685 equivalent to Tanzania shillings 1,500,000.

Authors' contributions

SM, AEN, KPM and PC conceived and designed the study. SM and PC jointly analysed the data, SM and AEN developed the paper; PC and KPM contributed to the writing of the manuscript and all authors reviewed the final manuscript.

Acknowledgements

We would like to give special thanks to the mothers and their infants with NTDs who participated in this research therefore helping in the realisation of the project. We would also like to thank the MUHAS Genetic Laboratory for hosting this research.

References

1. Merriam-Webster. Birth defect [homepage on the internet]. c2015 [cited 2016 Apr 27]. Available from: [http://www.merriam-webster.com/dictionary/birth +defect](http://www.merriam-webster.com/dictionary/birth+defect).
2. Christianson A, Howson CP, Modell B. March of dimes global report on birth defects. 2006. Pages Retrieved from http://www.marchofdimes.com/downloads/Birth_Defects_Report-PF.pdf. 2016.
3. Salih MA, Murshid WR, Seidahmed MZ. Epidemiology, prenatal management, and prevention of neural tube defects. Saudi Medical Journal. 2014;35(Suppl 1):S15.
4. Kishimba RS, Mpembeni R, Mghamba JM, Goodman D, Valencia D. Birth prevalence of selected external structural birth defects at four hospitals in Dar es Salaam, Tanzania, 2011–2012. Journal of global health. 2015 Dec;5(2).
5. Imbard A, Benoist JF, Blom HJ. Neural tube defects, folic acid and methylation. International journal of environmental research and public health. 2013 Sep 17;10(9):4352-89.
6. Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. The Lancet Neurology. 2013 Aug 31;12(8):799-810.
7. Zhang T, Lou J, Zhong R, Wu J, Zou L SY et al. Genetic variants in the folate pathway and the risk of neural tube defects: a meta-analysis of the published literature. PLoS one. 2013 Apr 4;8(4):e59570.
8. Kirke PN, Mills JL, Molloy AM, Brody LC, O'leary VB, Daly L et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. Bmj. 2004 Jun 24;328(7455):1535-6.
9. Hayati AR, Zainal AI, Tan GC, Ong LC, Khoo TB. MTHFR C677T polymorphism as a risk factor of neural tube defects in Malay: A Case Control Study. 2008;63(5):379–83.
10. Brody LC, Conley M, Cox C, Kirke PN, McKeever MP, Mills JL et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects .The American Journal of Human Genetics. 2002;Nov 30:71(5):1207-15.
11. Parle-McDermott A, Pangilinan F, O'brien KK, Mills JL, Magee AM, Troendle J et al. A common variant in MTHFD1L is associated with neural tube defects and mRNA splicing efficiency. Human mutation. 2009 Dec 1;30(12):1650-6.
12. Narisawa A, Komatsuzaki S, Kikuchi A, Niihori T, Aoki Y, Fujiwara K et al. Mutations in Genes Encoding the Glycine Cleavage System Predispose to Neural Tube Defects in Mice and Humans. Human Molecular Genetics, 2011 Dec 13;21(7):1496-503.
13. Lei Y-P, Zhang T, Li H, Wu B-L, Jin L, Wang H-Y. VANGL2 mutations in human cranial neural-tube defects. N Engl J Med. 2010;362(23):2232–5.
14. Kibar Z, Torban E, McDearmid JR, Reynolds A, Berghout J, Mathieu M et al. Mutations in VANGL1 associated with neural-tube defects. New England Journal of Medicine. 2007 Apr 5;356(14):1432-7.
15. De Marco P, Merello E, Consales A, Piatelli G, Cama A, Kibar Z et al. Genetic analysis of disheveled 2 and disheveled 3 in human neural tube defects. Journal of Molecular Neuroscience. 2013 Mar 1;49(3):582-8.

16. Schmittgen TD, Livak KJ. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method. 2001;402-8.
17. Dunlevy LP, Chitty LS, Burren KA, et al. Abnormal folate metabolism in fetuses affected by neural tube defects. *Brain*. 2007;130(Pt 4):1043-1049. doi:10.1093/brain/awm028

Figures

Figure 1

Relative gene expression profile for 8 selected genes analysed among 150 infants (NTD cases and controls) attending MNH and MOI